Site Search

... years. New York has seen declines in both cancer incidence and mortality from breakthroughs in research and treatment, but there is still a lot of work to be done. If New York aims to remain a national leader in cancer care, as I believe the Empire State is meant to be, our elected ... and diagnostic services. In this, Governor Hochul has the opportunity to make New York a health equity champion. There are steps she can take now as well as in the coming year to ensure equitable and impactful policy becomes law. Let’s walk through them, starting with actions ... two bipartisan bills limiting New Yorkers’ out-of-pocket health expenses. The first, A2085-A / S906-B, or the Colorectal Cancer Screening Cost Sharing Removal Act, requires that every state-regulated health plan covers 100% of the cost of colorectal cancer screening beginning at age ...

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) Pennsylvania Government Relations Director Donna Greco: “In 2024, ACS CAN was proud to see the Pennsylvania Legislature mobilize swiftly and in a bipartisan manner to bring the promise of precision medicine to more patients. Beginning in the new year, Act 39 of 2024 will make it so that all patients who can benefit and are insured ... programs are making it so that patients cannot access lifesaving care. ACS CAN is looking to address that in 2025 with legislation to eliminate cost-sharing for prostate cancer screenings for high-risk populations and ensure third-party prescription drug copay assistance always counts ...

Statement from American Cancer Society Cancer Action Network (ACS CAN) Government Relations Director Leo Almeida   COLUMBUS, OHIO – “As lawmakers dive into the 2023 legislative session, the American Cancer Society Cancer Action Network (ACS CAN) urges legislators to prioritize passing legislation to ease the burden of cancer on Buckeyes.  “ACS CAN calls on the legislature to increase access to biomarker testing, a game changer in the fight against cancer ... the right time,’ precision medicine has played a critical role in improving cancer outcomes. Despite its benefits, health insurance coverage of biomarker testing has not kept pace with innovations in treatment.  “Furthermore, copay accumulator legislation unanimously passed the House ...

... all residents have ready access to biomarker testing. "Access to biomarker testing is about identifying the most effective treatment—which can save lives. It is the pathway to precision medicine, which can make all the difference in the outcome of a patient's cancer treatment," said Matt Helder, government relations director at ACS CAN. "In Washington, insurance coverage for biomarker ... saving costs and eliminating life-altering side effects.  It’s notable that biomarker testing is increasingly important to the treatment of conditions outside of the cancer space, like arthritis and other autoimmune conditions, organ and tissue transplant, and rare diseases. Research ...